Subhashini Jagu

Health Science Administrator

Contact Information


Dr. Subhashini Jagu joined CBIIT in June 2020 as a health science administrator in the Office of Data Sharing (ODS). In this position, Dr. Jagu provides programmatic support for the Childhood Cancer Data Initiative (CCDI) and contributes to the development of policies and guidelines for data depositions

In her 20-year scientific career, Dr. Jagu has gained extensive experience in planning, performing, evaluating, and disseminating biomedical research. Her work on human papillomavirus (HPV) recently culminated in a patent that will aid in the treatment and prevention of HPV infection.

She also brings to CBIIT a strong history of project management. As a program director for the Cancer Target Discovery and Development (CTD2) Network within the Center for Cancer Genomics (CCG), she supported, administered, and evaluated complex scientific networks and initiatives. Dr. Jagu also was instrumental in developing data release policies, processes, and procedures for data deposition at the CTD2 Data Portal and Dashboard.

She has authored more than 30 peer review articles on a broad range of subjects, and she specializes in topics related to prophylactic vaccine development and understanding the mechanism of action of therapeutic compounds.


  • Childhood Cancer Data Initiative (CCDI)


  1. Aksoy BA, Dancík V, Smith K, Mazerik JN, Ji Z, Gross B, Nikolova O, Jaber N, Califano A, Schreiber SL, Gerhard DS, Hermida LC, Jagu S, Sander C, Floratos A, Clemons PA. CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database (Oxford), 2017: bax054.
  2. Cancer Target Discovery and Development Network. Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance. Mol Cancer Res, 2016; 14(8):675-82.
  3. Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Vaccine, 2015; 33(42):5553-5563.
  4. Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol. 2013; 87(11):6127-36.
  5. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated Multi-type L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines. J Natl Cancer Inst, 2009; 101(11):782-92